Advancing Brain Organoids from Research Models to Scalable Platforms
In this GEN webinar, Joseph Shultz (VP of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (VP of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. The post Advancing Brain Organoids from Research Models to Scalable Platforms appeared…
Panelists Ali Strtak and Fikri Birey discussed advancing brain organoids from research models to scalable platforms. Strtak, a product manager at Bio-Techne, shared her expertise in optimizing culture conditions and calcium imaging protocols for functional characterization of viral proteins. Birey, an assistant professor at Emory University School of Medicine, highlighted his lab's use of stem cell-derived brain organoids and assembloids to model neurodevelopmental disorders like autism, epilepsy, and schizophrenia.
Both emphasized the importance of reproducibility and standardizing organoid culture to make the models more accessible to researchers. Birey also mentioned the Brain Organoid Hub at Emory as a central resource for scalable and standardized human brain organoid research, aiming to bridge basic neurobiology with therapeutic discovery for precision medicine.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
